Posaconazole: new indications. Prevention of invasive mycosis and treatment of oropharyngeal candidiasis: no therapeutic advantage.
D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002180:Candidiasis, Oral / Q000188:drug therapy*; D017277:Drug Approval; D005060:Europe; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles